Skip to content
  • Contact us
  • Contact us
Back To News
  • Media

BMF Business (FR) French Tech : Vaccins, futur de la lutte contre le cancer ?

See Video here

Stay tuned

NEWS

  • Linkedin
  • 17 June 2025

Brenus is proud to be part of the French Delegation at BIOUS 2025 Let’s connect and share insights

Read more

NEWS

  • Poster
  • 25 April 2025

AACR 2025: Brenus Pharma presents late-breaking preclinical data of STC-1010

Read more

NEWS

  • Media
  • 20 September 2024

The Times Magazine : Brenus Pharma Secures $25 Million to Propel Clinical Trials for Precision Cancer Vaccines

Read more

NEWS

  • Media
  • 19 September 2024

EU Startup – Lyon-based Brenus Pharma raises €22.2 million for precision cancer vaccines

Read more

NEWS

  • Media
  • 18 September 2024

BMF Business (FR) French Tech : Vaccins, futur de la lutte contre le cancer ?

Read more

NEWS

  • Media
  • 18 September 2024

Les Echos (FR) – Brenus Pharma réunit 22 millions pour lancer les essais cliniques de son vaccin anticancer

Read more
Brenus Pharma

All rights reserved

INCREASE IMMUNOGENICITY

Brenus’ manufacturing process overpasses the lack of immunogenicity & educates the immune system  with visible and multi-specific targets

More about Haptenization & STC immunogenicity
Back to the page

REPRESENT HETEROGENEITY OF THE TARGETED INDICATION

Selection criteria of starting material (Allogeneic tumor cell lines)

  • Representative oncogenic drivers (TP53,BRAF,KRAS,…)
  • Cold & hot tumor cell lines
  • Resistances capacities (metabolic ; chemical & physical)
Back to the page

Increase antigenicity

Brenus’ manufacturing process overpasses the lack of antigenicity & educates the immune system  with a broad & higher quality range of tumor antigens

More about STC Antigenicity
Back to the page
  • Contact us
  • Contact us